source
- Edgewise Therapeutics' experimental heart drug meets Phase 2 endpoints in cardiomyopathy trialEdgewise Therapeutics reported that its oral candidate EDG-7500 achieved the predefined goals of a Phase 2 study in both obstructive and non‑obstructive hypertrophic cardiomyopathy. The trial demo…
- Biotech Converts Failed Trial Data into AI ModelA biotech startup recently faced a setback when a clinical trial did not achieve its primary goals. Rather than discarding the results, the company chose to analyze the data for new insights. The…